Who is sponsoring NCT03987594?

NCT03987594 is sponsored by Yonsei University.

What drugs are being tested in NCT03987594?

Interventions in NCT03987594: Transurethral fulguration of the Hunner lesion, Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion.

What condition does NCT03987594 study?

NCT03987594 studies Interstitial Cystitis, Bladder Pain Syndrome.

Is NCT03987594 still recruiting?

NCT03987594 is currently completed. Last updated 3 September 2019.

Last reviewed 2019-09-03 · How we verify

NCT03987594

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparing the Effect of Fulguration Versus Fulguration and Hydrodistension in Interstitial Cystitis/Bladder Pain Syndrome

Completed NA Last updated 3 September 2019

What this trial tests

NA trial testing Transurethral fulguration of the Hunner lesion in Interstitial Cystitis in 55 participants. Completed in 31 October 2018.

Timeline

1 August 2015

Primary endpoint
31 October 2018

31 October 2018

Quick facts

Lead sponsor	Yonsei University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	55
Start date	1 August 2015
Primary completion	31 October 2018
Estimated completion	31 October 2018
Sites	1 location across South Korea

Drugs / interventions tested

Transurethral fulguration of the Hunner lesion
Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion

Conditions studied

Interstitial Cystitis — all drugs for Interstitial Cystitis →
Bladder Pain Syndrome — all drugs for Bladder Pain Syndrome →

Sponsor

Yonsei University

Who can join

Adults 29 to 83, any sex, with Interstitial Cystitis or Bladder Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomized controlled trial. Subject population is adult patients with Hunner-type interstitial cystitis. The objective of this study is to compare the therapeutic effect between the two surgical modality; TUF (transurethral fulguration of the Hunner lesion) versus TUF+HD(addition of bladder hydrodistension prior to transurethral fulguration of the Hunner lesion).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prospective randomized controlled trial comparing fulguration versus fulguration and hydrodistension for Hunner-type interstitial cystitis/bladder pain syndrome.
Son HS, Yoon H, Lee HS, Kim JH. · · 2022 · cited 7× · PMID 35704106 · DOI 10.1007/s00345-022-04062-8

Verify or expand the search:

Other recruiting trials for Interstitial Cystitis

Currently open trials in the same condition.

NCT06299683 — Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment · NA · recruiting
NCT05696444 — Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) · NA · active not recruiting
NCT05485207 — Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome · EARLY_PHASE1 · active not recruiting
NCT04734847 — Motor Cortical Neuromodulation in Women With Interstitial Cystitis/Bladder Pain Syndrome · NA · recruiting
NCT00499317 — Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03987594 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 3 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03987594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing